Abstract
Direct inhibition of transcription factor complexes remains a central challenge in the discipline of ligand discovery. In general, these proteins lack surface involutions suitable for high-affinity binding by small molecules. Here we report the design of synthetic, cell-permeable, stabilized α-helical peptides that target a critical protein–protein interface in the NOTCH transactivation complex. We demonstrate that direct, high-affinity binding of the hydrocarbon-stapled peptide SAHM1 prevents assembly of the active transcriptional complex. Inappropriate NOTCH activation is directly implicated in the pathogenesis of several disease states, including T-cell acute lymphoblastic leukaemia (T-ALL). The treatment of leukaemic cells with SAHM1 results in genome-wide suppression of NOTCH-activated genes. Direct antagonism of the NOTCH transcriptional program causes potent, NOTCH-specific anti-proliferative effects in cultured cells and in a mouse model of NOTCH1-driven T-ALL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Darnell, J. E. Transcription factors as targets for cancer therapy. Nature Rev. Cancer 2, 740–749 (2002)
Artavanis-Tsakonas, S., Rand, M. D. & Lake, R. J. Notch signaling: cell fate control and signal integration in development. Science 284, 770–776 (1999)
Bray, S. J. Notch signalling: a simple pathway becomes complex. Nature Rev. Mol. Cell Biol. 7, 678–689 (2006)
Struhl, G. & Greenwald, I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398, 522–525 (1999)
Ye, Y., Lukinova, N. & Fortini, M. E. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature 398, 525–529 (1999)
De Strooper, B. et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518–522 (1999)
Fortini, M. E. & Artavanis-Tsakonas, S. The suppressor of hairless protein participates in notch receptor signaling. Cell 79, 273–282 (1994)
Petcherski, A. G. & Kimble, J. Mastermind is a putative activator for Notch. Curr. Biol. 10, R471–R473 (2000)
Wu, L. et al. MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptors. Nature Genet. 26, 484–489 (2000)
Li, L. et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nature Genet. 16, 243–251 (1997)
Joutel, A. et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383, 707–710 (1996)
Garg, V. et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270–274 (2005)
Ellisen, L. W. et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649–661 (1991)
Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269–271 (2004)
O’Neil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J. Exp. Med. 204, 1813–1824 (2007)
Pece, S. et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell Biol. 167, 215–221 (2004)
Fre, S. et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435, 964–968 (2005)
Uyttendaele, H. et al. Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development 122, 2251–2259 (1996)
Nicolas, M. et al. Notch1 functions as a tumor suppressor in mouse skin. Nature Genet. 33, 416–421 (2003)
Konishi, J. et al. γ-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 67, 8051–8057 (2007)
Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S. & Gabrilovich, D. I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103, 3503–3510 (2004)
Park, J. T. et al. Notch3 gene amplification in ovarian cancer. Cancer Res. 66, 6312–6318 (2006)
Miyamoto, Y. et al. Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3, 565–576 (2003)
Seiffert, D. et al. Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J. Biol. Chem. 275, 34086–34091 (2000)
Dovey, H. F. et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem. 76, 173–181 (2001)
Lleó, A. Activity of γ-secretase on substrates other than APP. Curr. Top. Med. Chem. 8, 9–16 (2008)
Riccio, O. et al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 9, 377–383 (2008)
Maillard, I. et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 104, 1696–1702 (2004)
Weng, A. P. et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol. Cell. Biol. 23, 655–664 (2003)
Nam, Y., Sliz, P., Song, L., Aster, J. C. & Blacklow, S. C. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 124, 973–983 (2006)
Wilson, J. J. & Kovall, R. A. Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell 124, 985–996 (2006)
Schafmeister, C. E., Po, J. & Verdine, G. L. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122, 5891–5892 (2000)
Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466–1470 (2004)
Del Bianco, C., Aster, J. C. & Blacklow, S. C. Mutational and energetic studies of Notch 1 transcription complexes. J. Mol. Biol. 376, 131–140 (2008)
Aster, J. C. et al. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol. Cell. Biol. 20, 7505–7515 (2000)
Hallis, T. M. et al. An improved β-lactamase reporter assay: multiplexing with a cytotoxicity readout for enhanced accuracy of hit identification. J. Biomol. Screen. 12, 635–644 (2007)
Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006)
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)
Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261–18266 (2006)
Weng, A. P. et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 20, 2096–2109 (2006)
Rao, S. S. et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 69, 3060–3068 (2009)
Lewis, H. D. et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem. Biol. 14, 209–219 (2007)
Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Med. 13, 1203–1210 (2007)
Becker, C. M. et al. A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am. J. Pathol. 168, 2074–2084 (2006)
Stubbs, M. C. et al. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia 22, 66–77 (2008)
Real, P. J. et al. γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Med. 15, 50–58 (2009)
Nam, Y., Weng, A. P., Aster, J. C. & Blacklow, S. C. Structural requirements for assembly of the CSL·intracellular Notch1·Mastermind-like 1 transcriptional activation complex. J. Biol. Chem. 278, 21232–21239 (2003)
Chiang, M. Y. et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J. Clin. Invest. 118, 3181–3194 (2008)
Williams, R. M. & Im, M. N. Asymmetric synthesis of monosubstituted and α, α-disubstituted α-amino acids via diastereoselective glycine enolate alkylations. J. Am. Chem. Soc. 113, 9276–9286 (1991)
Chen, Y. H., Yang, J. T. & Chau, K. H. Determination of the helix and β form of proteins in aqueous solution by circular dichroism. Biochemistry 13, 3350–3359 (1974)
Acknowledgements
We thank S. Schreiber and the Broad Institute Chemical Biology Program for discussions and access to instrumentation; J. Rocnik for assistance in the establishment of the T-ALL murine model; A. Ferrando for providing GSI microarray data; M. Hancock and Invitrogen for providing β-lactamase HeLa reporter clones; K. Ross and A. Subramanian for conversations and guidance about GSEA; and S. Gupta and the Broad Institute Microarray Core. This work was supported by a Specialized Center of Research grant from the Leukaemia & Lymphoma Society (to J.E.B., J.C.A., S.C.B.), an AACR Centennial Pre-doctoral Research Fellowship in Cancer Research (to R.E.M.), the American Society of Hematology (to J.E.B.), MCCB-NIH Training Grant No. 5T32GM007598 (to R.E.M.), the Human Frontier Science Program (to C.D.), and the Harvard & Dana Farber Program in Cancer Chemical Biology (to J.E.B., R.E.M., G.L.V.). The project has been funded in part with Federal funds from the National Cancer Institute’s Initiative for Chemical Genetics, National Institutes of Health, under Contract No. N01-CO-12400. Histology and immunohistochemical staining was performed in the Dana Farber/Harvard Cancer Center Specialized Histopathology Services Core Laboratory.
Author Contributions R.E.M., G.L.V. and J.E.B. conceptualized the study, designed the experiments, interpreted data, and wrote the manuscript. Design, synthesis and biological characterization of SAHM peptides was performed by R.E.M. C.D.B., J.C.A. and S.C.B. contributed key reagents and analysed data. R.E.M., M.C., T.N.D., J.C.A., A.L.K., D.G.G. and J.E.B. established the bioluminescent T-ALL model, designed and performed in vivo experiments and analysed data.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
[COMPETING INTERESTS: G.L.V. is a shareholder in and paid consultant of Aileron Therapeutics, which has been granted a license by Harvard University and the Dana Farber Cancer Institute to develop the stapled peptide technology.]
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1 - 8 with Legends and Supplementary Tables 1 - 2. (PDF 3034 kb)
Rights and permissions
About this article
Cite this article
Moellering, R., Cornejo, M., Davis, T. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182–188 (2009). https://doi.org/10.1038/nature08543
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nature08543
This article is cited by
-
The Notch signaling pathway: a potential target for cancer immunotherapy
Journal of Hematology & Oncology (2023)
-
Cooperative NF-κB and Notch1 signaling promotes macrophage-mediated MenaINV expression in breast cancer
Breast Cancer Research (2023)
-
Targeting the SOX2/CDP protein complex with a peptide suppresses the malignant progression of esophageal squamous cell carcinoma
Cell Death Discovery (2023)
-
Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains
Nature Biotechnology (2023)
-
Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides
Nature Communications (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.